A comparison of treatment cost and benefit depends on the period and whose costs are counted. This simulation used data from the SURMOUNT-5 trial to project lifetime results from a U.S. societal perspective [1].
What the model projected
Compared with semaglutide, tirzepatide was projected to cost $41,688 less per person and yield 0.506 additional quality-adjusted life years. The model also projected 70 fewer cases of type 2 diabetes and 10 fewer cardiovascular disease cases per 1,000 patients [1].
The model used changes in weight and other risk factors to estimate later outcomes. It counted health care and wider societal costs, including lost productivity. The trial did not observe those lifetime outcomes.
Why assumptions and perspective matter
Research on how long people stay on GLP-1 treatment shows why results from one care setting may be difficult to carry over to another. The lifetime estimates depend on the model's treatment, cost and risk assumptions.
The study includes authors affiliated with Eli Lilly, which makes tirzepatide. The projected difference in societal costs cannot be used as an individual prescription quote.